

Supplementary Data

Supplementary Table 1. Clinical Characteristics of the Cohort

Clinical Data	Type 2 Diabetes (Validation Cohort)	PREVADIAB2 (General Population Cohort)
n	553	985
Women, n (%)	232 (42)	590 (60)
Age (years)	66 [59, 72]	62 [53, 70]
BMI (Kg/m ²)	29 [27, 32]	27 [24, 30]
Waist circumference (cm)	99 [92, 108]	96 [89, 102]
Type 2 Diabetes		
Normoglycemia, n (%)	0 (0)	713 (72)
Prediabetes, n (%)	0 (0)	214 (22)
Diabetes, n (%)	985 (100)	58 (6)
Diabetes duration (years)	13 [6,20]	NA
Diabetes complications, n (%)	174 (31)	NA
Metabolic profile		
HbA1c, %	7.9 [6.9, 9.2]	5.5 [5.2, 5.8]
Cholesterol, mg/dL HDL	45 [38, 53]	52 [44, 61]
Cholesterol, mg/dL LDL	114 [92, 139]	135 [116, 158]
Cholesterol, mg/dL	169 [146, 199]	198 [176, 225]
Triglycerides, mg/dL	156 [111, 219]	103 [78, 138]
Liver function		
ALT, U/L	21 [16, 32]	21 [16, 27]
AST, U/L	20 [17, 26]	23 [20, 27]
GGT, U/L	28 [19, 43]	22 [16, 33]
Platelets, 10 ³ /uL	230 [190, 271]	NA
Fibroscan		
Steatosis, n (%)	401 (73)	NA
F0, n (%)	291 (53)	NA

F1, n (%)	128 (23)	
F2, n (%)	46 (8)	
F3, n (%)	45 (8)	
F4, n (%)	43 (8)	
FAST Score	0.097 [0.043, 0.242]	NA
Rule in (>0.67), n (%)	30 (5)	
Rule out (<0.35), n (%)	457 (82) (96 - 17)	
FIB-4 score	1.23 [0.95, 1.69]	NA
Rule in (>1.3), n (%)	251 (45)	

**Supplementary Table 2 - Diagnostic Performance of FNI and FIB-4 for
Fibrotic NASH and Cutoff Values in Diabetes Validation Cohort**

Fibrotic NASH definition	FAST score > 0.35
Fibrotic NASH, n (%)	96 (17)
FNI AUROC (95% CI) (DeLong)	0.889 [0.8525-0.9261]
FIB-4 AUROC (95% CI) (DeLong)	0.673 [0.6162-0.7304]
FNI ≥0.30, n (%)	253 (45)
Sensitivity	0.92
Specificity	0.64
PPV	0.35
NPV	0.97
FNI ≤0.10 (Rule-out zone), n (%)	483 (87)
Sensitivity	0.99
Specificity	0.15
PPV	0.19
NPV	0.99
FNI ≥0.33 (Rule-in zone), n (%)	232 (42)
Sensitivity	0.91
Specificity	0.68
PPV	0.38
NPV	0.97
FIB-4 ≥1.3, n (%)	251(45)
Sensitivity	0.66
Specificity	0.59
PPV	0.25
NPV	0.89